Correlation of molecular markers with clinical outcome in GBM patients radiation treated with or without gefitinib
View Patent ↗Interestingly, for prognosis, the significant biomarkers for Gefitinib-treated GBM patients (RTOG 0211) appeared to differ compared to historical, RT and non-Gefitinib-treated GBM patients. In Gefitinib-treated patients, those with higher levels of nuclear pAKT driven by PTEN loss, higher levels of nuclear pMAPK, and lower levels of nuclear pmTOR had significantly worse clinical outcomes. In contrast, in non-Gefitinib-treated patients, patients with PTEN-deficiency, and higher levels of EGFRvIII, total EGFR, IGFR1, NFkB and lower levels of nuclear Survivin appeared to have adverse clinical outcomes, highlighting the treatment-dependency of these biomarkers.
1. A method of determining a prognosis of a patient harboring a glioblastoma multiforme (GBM) tumor comprising:
assessing a subcellular concentration or a relative concentration of one or more protein biomarkers selected from a group consisting of PTEN and pMAPK in a tissue specimen comprising GBM cells obtained from a patient harboring a GBM tumor;
classifying a patient having a high nuclear pMAPK or intermediate cytoplasm to nuclear PTEN ratio as having a good prognosis if the patient is treated with radiation therapy alone, and
administering to the patient classified as having a good prognosis radiation therapy alone.
2. A method of determining a prognosis of a patient harboring a glioblastoma multiforme (GBM) tumor comprising:
assessing a subcellular concentration or a relative concentration of two or more protein biomarkers selected from a group consisting of EGFR, Src and NFkB in a tissue specimen comprising GBM cells obtained from a patient harboring a GBM tumor;
classifying a patient having an intermediate level of EGFR, high level of NFkB and/or intermediate to high Src level as having a poor prognosis if the patient is treated with radiation therapy combined with gefitinib, and
withholding from the patient classified as having a poor prognosis the administration of radiation therapy in combination with gefitinib.
3. A method of determining a prognosis of a patient harboring glioblastoma multifonne (GBM) tumor comprising:
assessing a subcellular concentration or a relative concentration of two or more protein biomarkers selected from a group consisting of EGFR, Src, and NFkB in a tissue specimen comprising GBM cells obtained from a patient harboring a GBM tumor;
classifying a patient having a low EGFR level, low Src level and/or low to intermediate NFkB level as having a good prognosis if the patient is treated with radiation therapy combined with gefitinib; and
administering to the patient classified as having a good prognosis radiation therapy in combination with gefitinib.
4. A method of determining prognosis or relative survival risk of a patient harboring a glioblastoma multiforme (GBM) tumor if the patient is treated with radiation therapy combined with gefitinib comprising:
assessing a concentration or a relative concentration of two or more biomarkers selected from a group consisting of EGFR, NFkB and Src in a tissue specimen comprising GBM cells obtained from a patient harboring a GBM tumor;
classifying a patient with a positive expression of all biomarkers as having a poor prognosis for survival; no expression of all biomarkers as having a good prognosis for survival; and positive expression of any two biomarkers as having a relatively moderate prognosis for survival, and
administering to the patient classified as having a good or moderate prognosis radiation therapy in combination with gefitinib.